These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1576570)

  • 1. Prophylactic aspirin and the elderly population.
    Dalen JE; Goldberg RJ
    Clin Geriatr Med; 1992 Feb; 8(1):119-26. PubMed ID: 1576570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin to prevent heart attack and stroke: what's the right dose?
    Dalen JE
    Am J Med; 2006 Mar; 119(3):198-202. PubMed ID: 16490462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
    Cotter G; Cannon CP; McCabe CH; Michowitz Y; Kaluski E; Charlesworth A; Milo O; Bentley J; Blatt A; Krakover R; Zimlichman R; Reisin L; Marmor A; Lewis B; Vered Z; Caspi A; Braunwald E;
    Am Heart J; 2003 Apr; 145(4):622-7. PubMed ID: 12679757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin for prevention of myocardial infarction. A double-edged sword.
    Bar-Dayan Y; Levy Y; Amital H; Shoenfeld Y
    Ann Med Interne (Paris); 1997; 148(6):430-3. PubMed ID: 9538376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne].
    Cambou JP; Lablache-Combier B; Marques-Vidal P; Ruidavets JB; Branchu MP; Ferrières J
    Ann Cardiol Angeiol (Paris); 1994 Dec; 43(10):588-93. PubMed ID: 7864551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
    Christiaens L; Ragot S; Mergy J; Allal J; Macchi L
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin use in the prevention of cardiovascular events.
    Crutcher JM; Mallonee S; Daniels C
    J Okla State Med Assoc; 2007 Oct; 100(10):383-7. PubMed ID: 18085095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
    Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of antithrombotic drugs in artery disease.
    Gallus AS
    Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
    Smith EE; Cannon CP; Murphy S; Feske SK; Schwamm LH
    Am Heart J; 2006 Feb; 151(2):338-44. PubMed ID: 16442896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
    Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood thinning in heart patients].
    Meier B
    Ther Umsch; 1995 Oct; 52(10):661-71. PubMed ID: 7482377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
    Kassem-Moussa H; Mahaffey KW; Graffagnino C; Tasissa G; Sila CA; Simes RJ; White HD; Califf RM; Bhapkar MV; Newby LK;
    Am Heart J; 2004 Sep; 148(3):439-46. PubMed ID: 15389230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
    García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
    Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary artery disease in women.
    Chiamvimonvat V; Sternberg L
    Can Fam Physician; 1998 Dec; 44():2709-17. PubMed ID: 9870124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.